Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy

Diabetes

Volumn 56, Issue 7, 2007, Pages 1834-1841

  Westermann, Dirk ^a   Van Linthout, Sophie ^a   Dhayat, Sameer ^a   Dhayat, Nasser ^a   Escher, Felicitas ^a   Bücker Gärtner, Carola ^a   Spillmann, Frank ^a   Noutsias, Michel ^a   Riad, Alexander ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a,b  

^a Campus Benjamin Franklin ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; COLLAGEN; CYTOKINE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN CONVERTING ENZYME INHIBITOR; PLACEBO; PRALNACASAN; PROTEIN BAX; PROTEIN BLC 2; PROTEIN KINASE B; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INHIBITION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARDIOMYOPATHIES; CASPASE 1; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FIBROSIS; HEART; INFLAMMATION; MALE; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT;

EID: 34347405900     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1662     Document Type: Article

References (42)

1. Spector KS: Diabetic cardiomyopathy. Clin Cardiol 21:885-887, 1998
2. Bell DS: Diabetic cardiomyopathy. Diabetes Care 26:2949-2951, 2003
3. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, Pauschinger M, Pesquero JB, Bader M, Schultheiss HP, Noutsias M: Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18:828-835, 2004
4. Tschope C, Spillmann F, Rehfeld U, Koch M, Westermann D, Altmann C, Dendorfer A, Walther T, Bader M, Paul M, Schultheiss HP, Vetter R: Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J 18:1967-1969, 2004
5. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C: Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56:641-646, 2007
6. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, Schimke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, Noutsias M: Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 19:2057-2059, 2005
7. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, Riad A, Pauschinger M, Schultheiss HP, Tschope C: Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 49:2507-2513, 2006
8. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, Wang C, Lee JC, Feuerstein GZ, Yue TL: Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99:1685-1691, 1999
9. Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S, Schaefer E, Walsh K, Rosenzweig A, Torella D, Nurzynska D, Kajstura J, Leri A, Anversa P, Sussman MA: Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res 94:884-891, 2004
10. Latronico MV, Costinean S, Lavitrano ML, Peschle C, Condorelli G: Regulation of cell size and contractile function by Akt in cardiomyocytes. Ann N Y Acad Sci 1015:250-260, 2004
11. Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R: ICE/caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs 10:1207-1209, 2001
12. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al.: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356:768-774, 1992
13. Ayala JM, Yamin TT, Egger LA, Chin J, Kostura MJ, Miller DK: IL-1 beta-converting enzyme is present in monocytic cells as an inactive 45-kDa precursor. J Immunol 153:2592-2599, 1994
14. Kronheim SR, Mumma A, Greenstreet T, Glackin PJ, Van Ness K, March CJ, Black RA: Purification of interleukin-1 beta converting enzyme, the protease that cleaves the interleukin-1 beta precursor. Arch Biochem Biophys 296:698-703, 1992
15. Walther T, Steendijk P, Westermann D, Hohmann C, Schulze K, Heringer-Walther S, Schultheiss HP, Tschope C: Angiotensin deficiency in mice leads to dilated cardiomyopathy. Eur J Pharmacol 493:161-165, 2004
16. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuhl U, Schultheiss HP: Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99:2750-2756, 1999
17. Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, Kuhl U: Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit 8:MT59-MT71, 2002
18. Pauschinger M, Doerner A, Remppis A, Tannhauser R, Kuhl U, Schultheiss HP: Differential myocardial abundance of collagen type I and type III mRNA in dilated cardiomyopathy: effects of myocardial inflammation. Cardiovasc Res 37:123-129, 1998
19. Borges GR, de Oliveira M, Salgado HC, Fazan R Jr: Myocardial performance in conscious streptozotocin diabetic rats. Cardiovasc Diabetol 5:26, 2006
20. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L: Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113:544-554, 2006
21. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201-1206, 1996
22. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. Part II. Causal mechanisms and treatment. Circulation 105:1503-1508, 2002
23. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W: Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11:738-746, 2003
24. Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A: The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 308:583-590, 2004
25. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA: Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 98:2871-2876, 2001
26. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA: IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 98:13249-13254, 2001
27. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, Kurimoto M, Tanimoto T, Flavell RA, Sato V, Harding MW, Livingston DJ, Su MS: Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275:206-209, 1997
28. Linton SD: Caspase inhibitors: a pharmaceutical industry perspective. Curr Top Med Chem 5:1697-1717, 2005
29. Mohr S, Xi X, Tang J, Kern TS: Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 51:1172-1179, 2002
30. Dinarello CA: Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci 856:1-11, 1998
31. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H, Leimer AH, Cheronis J: Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A 96:6261-6266, 1999
32. Siegmund B: Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 64:1-8, 2002
33. Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, Cohen-Solal A, Seidler T, Hasenfuss G, Chvatchko Y, Shah AM, Tedgui A: Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 18:1752-1754, 2004
34. Mann DL: Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65:81-101, 2003
35. Wyman TH, Dinarello CA, Banerjee A, Gamboni-Robertson F, Hiester AA, England KM, Kelher M, Silliman CC: Physiological levels of interleukin-18 stimulate multiple neutrophil functions through p38 MAP kinase activation. J Leukoc Biol 72:401-409, 2002
36. Montanari D, Yin H, Dobrzynski E, Agata J, Yoshida H, Chao J, Chao L: Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 54:1573-1580, 2005
37. Syed FM, Hahn HS, Odley A, Guo Y, Vallejo JG, Lynch RA, Mann DL, Bolli R, Dorn GW 2nd: Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res 96:1103-1109, 2005
38. Jani A, Ljubanovic D, Faubel S, Kim J, Mischak R, Edelstein CL: Caspase inhibition prevents the increase in caspase-3, -2, -8 and -9 activity and apoptosis in the cold ischemic mouse kidney. Am J Transplant 4:1246-1254, 2004
39. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL: Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 66:2202-2213, 2004
40. Fang ZY, Prins JB, Marwick TH: Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543-567, 2004
41. Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R, Okada Y, Nakanishi I: Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 46:32-36, 1993
42. Mann DL: Targeted anticytokine therapy and the failing heart. Am J Cardiol 95:9C-16C, 2005